Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.52 |
| ▸ | FAP | Q12884 | 1/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.39 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18602052 | 0.88 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL15810602 | 0.88 | DPP4 (0.40) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1031751 | 0.85 | PAX8 (0.47) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL16566040 | 0.83 | DPP4 (0.44) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL23169746 | 0.81 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL12285003 | 0.81 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL1034777 | 0.81 | DPP4 (0.53) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL15444284 | 0.81 | DPP4 (0.42) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL14623137 | 0.79 | DPP9 (0.41) | DPP4DPP8DPP9DPP7FAP | |
| SCHEMBL15606228 | 0.79 | DPP9 (0.42) | DPP4DPP8DPP9DPP7FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2277884-B1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | TIANJIN HEMAY ONCOLOGY PHARMACEUTICAL CO LTD (CN) | 2017-08-23 | — | — | EP | disclosed |
| US-9115165-B2 | Tetracyclic anthraquinone antibiotic derivatives with high activity, process for preparing the same and use thereof | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2015-08-25 | — | — | US | disclosed |
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | TIANJIN HEMAY BIO-TECH CO., LTD. (CN) | 2011-09-15 | — | — | US | disclosed |
| EP-2277884-A1 | ANTHRACYCLINE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PREPARATION METHODS AND USES THEREOF | Tianjin Hemay Bio-Tech Co., Ltd. (CN) | 2011-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224161-A1 | TETRACYCLIC ANTHRAQUINONE ANTIBIOTIC DERIVATIVES WITH HIGH ACTIVITY, PROCESS FOR PREPARING THE SAME AND USE THEREOF | DHPS, TBCA, ANTXR2 | DPP4 3343/4885DPP8 3954/4885DPP9 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.